Theravance Biopharma
Theravance Biopharma Inc is an American biopharmaceutical company focused on discovering, developing, and commercializing organ-selective medicines for respiratory and gastrointestinal diseases. The company commercializes Yupelri (revefenacin), an FDA-approved once-daily nebulized bronchodilator for chronic obstructive pulmonary disease (COPD) in collaboration with Viatris, alongside holding royalty rights to Trelegy Ellipta (commercialized by GSK). Principal revenues derive from commercial sales of Yupelri, licensing milestone payments, and recurring product royalty fees from Trelegy sales. Core end markets encompass pulmonology clinics, hospital respiratory departments, and COPD prescription patients across North America and international markets. Theravance Biopharma holds an established position in the pharmaceutical biopharmaceutical sector for nebulized maintenance bronchodilators. The corporation is incorporated in the Cayman Islands, headquartered in South San Francisco, California, and its common stock trades on Nasdaq.
3 of the funds FundTelligence covers report a position in Theravance Biopharma.
- Legal name
- THERAVANCE BIOPHARMA
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 3
Funds holding Theravance Biopharma
- KLP AksjeGlobal Small Cap Flerfaktor — KLP · 0.16 % (full portfolio disclosed, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.01 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)